3-噻吩甲酰胺 | 51460-47-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-噻吩甲酰胺
• 中文别名: 3-噻吩羧胺
• 英文名称: 3-carbamoylthiophene
• 英文别名: thiophene-3-carboxamide；3-thiophenecarboxamide；3-thiophenamide
• CAS: 51460-47-0
• 化学式: C₅H₅NOS
• mdl: MFCD05664206
• 分子量: 127.167
• InChiKey: DAUYIKBTMNZABP-UHFFFAOYSA-N

物化性质

• 熔点：
  181-184 °C (lit.)
• 沸点：
  313.5±15.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2934999090
• 储存条件：
  将贮藏器密封，并将其放入一个紧密封装的容器中。存放在阴凉、干燥的地方。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3-Thiophenecarboxamide
CAS-No. : 51460-47-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C5H5NOS
Molecular Weight : 127,16 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 181 - 184 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-噻吩甲酰胺 在 4-二甲氨基吡啶 、 potassium fluoride 、 [Pd(IPr)(cin)Cl] 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 15.0h， 生成 苯基-3-噻吩基-甲酮
  参考文献：
  名称：

  [Pd（NHC）（cin）Cl]在室温下使伯酰胺衍生的亲电试剂在Suzuki-Miyaura交叉偶联的通用方法

  摘要：

  据报道，室温下，通常遇到的主要苯甲酰胺的Suzuki-Miyaura交叉偶联是一种通用的，高度选择性的方法。酰胺氮的位点选择性N，N -di-Boc活化（叔丁氧基羰基活化）与稳定的空气和水分稳定的，定义明确的和高反应性的[Pd（NHC）（cin）Cl ]（NHC = N-杂环卡宾； cin =肉桂基）提供了一种从伯酰胺高收率制备联芳基酮的高效途径。酰胺酰基交叉偶联首次获得了> 1000的TON。

  DOI：

  10.1021/acs.orglett.7b03191
• 作为产物：
  描述：

  3-甲基噻吩 在 叔丁基过氧化氢 、 iron(III) chloride hexahydrate 、 tetrabutylammonium iodide 、 Ammonium hydroxide 作用下， 以 水 为溶剂， 反应 18.0h， 以50%的产率得到3-噻吩甲酰胺
  参考文献：
  名称：

  甲基芳烃与氨之间的氧化偶联：芳族伯酰胺的直接方法

  摘要：

  已经开发了一种使用叔丁基氢过氧化物和四丁基碘化铵（TBHP / TBAI）氧化系统与氯化铁（III）共同催化的甲基芳烃和氨水之间的直接氧化酰胺化方法。两种偶联伙伴均以其天然形式使用，以使之前的官能化变得不必要，并提供了一种简便的方法来制备芳族伯酰胺。

  DOI：

  10.1002/adsc.201500310

文献信息

• A general and practical oxidation of alcohols to primary amides under metal-free conditions
  作者：Xiao-Feng Wu、Muhammad Sharif、Jian-Bo Feng、Helfried Neumann、Anahit Pews-Davtyan、Peter Langer、Matthias Beller

  DOI：10.1039/c3gc40668g

  日期：——

  A general procedure for oxidation of both benzyl alcohols and alkyl alcohols to primary amides under catalyst free conditions has been developed. 34 examples of primary amides were produced from their corresponding alcohols in moderate to excellent yields. This is a practical procedure for primary amides synthesis; water and tert-butanol are the only by-products. A commercial drug, Piracetam, was prepared

  一般程序 氧化作用 两者 苄醇 和 烷基醇 到 伯酰胺 在下面 催化剂自由条件得到了发展。34个例子伯酰胺 是从它们对应的 酒类产量中等至优异。这是一个实际的程序伯酰胺 合成; 水 和 叔丁醇是唯一的副产品。商业广告药品， 拉西坦一步制备了，收率为73％。
• Nickel-Catalyzed Diaryl Ketone Synthesis by N–C Cleavage: Direct Negishi Cross-Coupling of Primary Amides by Site-Selective <i>N</i>,<i>N</i>-Di-Boc Activation
  作者：Shicheng Shi、Michal Szostak

  DOI：10.1021/acs.orglett.6b02952

  日期：2016.11.18

  the first amide cross-coupling by direct metal insertion of simple and readily available primary amides. The overall strategy by N,N-di-Boc activation/metal insertion is suitable for a broad range of coupling protocols via acylmetals. Mechanistic experiments suggest high reactivity of N,N-di-Boc activated 1° amides in direct amide C–N cross-couplings.

  首次报道了通过位点选择性N，N -di-Boc活化和镍催化的组合实现的伯酰胺的一般Negishi酰化反应。稳定的，廉价的镍催化剂促进了反应的进行。该反应显示出优异的官能团相容性，可通过选择性N-C裂解获得官能化的二芳基酮。最值得注意的是，该方案代表了通过直接金属插入简单易得的伯酰胺而进行的第一个酰胺交叉偶联。N，N -di-Boc活化/金属插入的整体策略适用于广泛的通过酰基金属的偶联方案。力学实验表明N，N具有高反应活性-di-Boc在酰胺直接C–N交叉偶联中活化了1°酰胺。
• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• Metal-Free Nitrogen- and Boron-Codoped Mesoporous Carbons for Primary Amides Synthesis from Primary Alcohols via Direct Oxidative Dehydrogenation
  作者：Sensen Shang、Pei-Pei Chen、Lianyue Wang、Ying Lv、Wei-Xue Li、Shuang Gao

  DOI：10.1021/acscatal.8b02889

  日期：2018.11.2

  Metal-free catalysts show environmental friendliness and cost-effectiveness, as well as less susceptibility to poisoning over metal and metal oxide catalysts. In this respect, we present the synthesis and characterization of metal-free mesoporous nitrogen- and boron-codoped nanocarbon (meso-N,B/C), which exhibits good catalytic performance with conversion of 89% and selectivity of 83% toward amide

  不含金属的催化剂显示出环境友好性和成本效益，并且较金属和金属氧化物催化剂更不容易中毒。在这一方面，我们介绍了无金属的介孔氮和硼共掺杂的纳米碳（介孔N，B / C）的合成和表征，该化合物表现出良好的催化性能，对酰胺合成的转化率为89％，选择性为83％。在氧气气氛下，使用NH 4 OAc作为氨气，从伯醇中分离得到。通过热解富氮配体4,5-二氮杂芴-9-一嗪（DAA）和H 3 BO 3来执行简便的共掺杂合成策略分别作为氮和硼含量调节剂。显着的是，对照实验表明，该反应是通过醛-氨缩合后的羟胺的直接氧化脱氢而进行的，这与以前的文献明显不同。密度泛函理论（DFT）计算进一步证明，对苯甲酰胺的选择性偏爱很大程度上得益于氧分子通过与掺杂在催化剂中的B原子相互作用而产生的强吸附和增强的活性。内消旋N，B / C催化剂中的活性中心被认为是石墨碳片中与N结合的B原子。这一发现为开发无金属催化改性碳材料开辟了道路。
• Substituted alkylamine derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05234946A1

  公开（公告）日：1993-08-10

  The substituted alkylamine derivatives represented by formula (I) ##STR1## wherein R.sup.1 represents (a) substituted or unsubstituted C.sub.2-6 alkenyl group, (b) substituted or unsubstituted C.sub.3-6 cycloalkenyl group, (c) substituted or unsubstituted C.sub.2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru.sup.11 -Ar wherein R.sup.11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; ##STR2## represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R.sup.7, X and Y are linking groups, R.sup.2 is H or lower alkyl, R.sup.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R.sup.4 and R.sup.5 are independently hydrogen or halogen atoms, R.sup.6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-me thyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.

  根据您的要求，以下是公式(I)所代表的取代烷基胺衍生物的中文翻译： “式中，R1 代表（a）取代或未取代的C2-6烯基团，（b）取代或未取代的C3-6环烯基团，（c）取代或未取代的C2-6炔基团，（d）取代或未取代的芳基团，（e）取代或未取代的杂环团，（f）可能被取代的融合杂环团，或（g）由公式Ru11-Ar表示的团，其中R11是杂环团，Ar是5或6成员的芳香环，其中可能含有杂N、O或S原子，并且可能被取代；##STR2##代表一个5或6成员的芳香环，其中可能含有杂N、O或S原子，并且可能被R7、X和Y是连接基团，R2是H或低级烷基，R3是氢、低级烷基、低级烯基、低级炔基或低级环烷基，R4和R5是独立的是氢或卤素原子，R6代表（a）可能是不饱和的取代或未取代的链状烃基团，（b）取代或未取代的环烷基团，或（c）取代或未取代的苯基团，或其非毒性的盐。以下是一个代表性的例子：(E)-N-(6-6-二甲基-2-庚烯-4-炔基)-N-乙基-3-[4-(3-噻吩基)-2-噻吩基甲氧基]苄胺盐酸盐。这些取代烷基胺衍生物作为药物很有用，特别适用于治疗和预防高胆固醇血症、高脂血症和动脉粥样硬化。”